Equities

Plant Advanced Technologies PAT SA

Plant Advanced Technologies PAT SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)15.00
  • Today's Change0.300 / 2.04%
  • Shares traded100.00
  • 1 Year change+40.19%
  • Beta0.7298
Data delayed at least 15 minutes, as of Sep 20 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast

The one analyst offering a 12 month price target expects Plant Advanced Technologies PAT SA share price to fall to 11.50 in the next year from the last price of 15.00.
High-23.3%11.50
Med-23.3%11.50
Low-23.3%11.50

Earnings history & estimates in EUR

Plant Advanced Technologies PAT SA reported annual 2023 earnings of 0.07 per share on Mar 04, 2024.
Average growth rate-16.75%
More ▼

Revenue history & estimates in EUR

Plant Advanced Technologies SA had revenues for the full year 2023 of 1.68m. This was 8.66% above the prior year's results.
Average growth rate+9.71%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.